Discover the groundbreaking approach of using amniotic membrane dressings for treating aplasia cutis in newborns, a promising advancement in neonatal care.
– by James
Note that James is a diligent GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
Amniotic membrane dressings for treatment of aplasia cutis in newborns.
Kadivar et al., Pediatr Dermatol 2024
<!– DOI: 10.1111/pde.15540 //–>
https://doi.org/10.1111/pde.15540
This study highlights the efficacy of amniotic membrane (AM) dressings in treating skin defects caused by Aplasia cutis congenita (ACC), a rare congenital condition. Conducted on five neonates at the Children’s Medical Center in Tehran, Iran, between 2018 and 2022, the research focused on wounds larger than 1 cm2. The findings revealed that AM dressings facilitated re-epithelialization, with the healing process averaging around 3.5 weeks. Notably, no hypertrophic scarring was observed, indicating satisfactory cosmetic outcomes. The length of hospital stay varied from 2 to 6 weeks, based on wound size. This study contributes to the current literature by demonstrating the potential of AM dressings as an effective treatment for ACC skin defects, offering a promising alternative to traditional methods like skin grafting, especially in terms of healing time and cosmetic results.